Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $0.7188
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Mar 27, 26 |
| Chardan Capital |
| maintain |
| Buy |
| Buy |
| Dec 4, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Nov 21, 25 | B. Riley Securities | maintain | Buy | Buy |
| Nov 19, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 8, 25 | Chardan Capital | maintain | Buy | Buy |
| Jun 26, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 27, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 8, 25 | Chardan Capital | maintain | Buy | Buy |
| Mar 24, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 27.46 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 10.74 | Oscillator | Buy |
| Williams %R (14) | -80.93 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.07 (Hist -0.01) | Oscillator | Strong Sell |
| Average Directional Index (14) | 29.81 (+DI 14.3 / -DI 25.9) | Trend | Strong Sell |
| EMA 20 | 0.82 | MA | Strong Sell |
| SMA 20 | 0.84 | MA | Strong Sell |
| EMA 50 | 0.91 | MA | Strong Sell |
| SMA 50 | 0.94 | MA | Strong Sell |
| SMA 200 | 1.08 | MA | Strong Sell |
Stock news · updated daily
PURCHASE, N.Y., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, has aligned with the U.S. Food and Drug Administration (FDA) on key elements of a Phase 3 study in dementia with Lewy bodies (DLB) including patient selection, dose, duration, and endpoints.
- An additional five years of patent protection may be possible through a standard extension - - An additional five years of patent protection may be possible through a standard extension -
October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3 October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3
PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company's president and CEO, Lisa Ricciardi intends to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. Eastern Time. During her presentation, Ms. Ricciardi will discuss progress on the Company's development of zervimesine for Alzheimer's disease and dementia with Lewy bodies (DLB).
Cognition Therapeutics, Inc. (CGTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.11 per share a year ago.
PURCHASE, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the “Company” or “Cognition”), today reported financial results for the second quarter ended June 30, 2026, and provided a business update.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -0.06 | -0.04 | Beat 36.8% | — |
| May 7, 2026 | -0.06 | -0.05 | Beat 16.7% | — |
| Mar 26, 2026 | -0.06 | -0.02 | Beat 66.7% | — |
| Nov 6, 2025 | -0.07 | -0.06 | Beat 14.3% | — |
| Aug 7, 2025 | -0.12 | -0.11 | Beat 8.3% | — |
| May 7, 2025 | -0.12 | -0.14 | Miss -16.7% | — |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 17, 26 | Khattar Jack A. | director | A-Award | 25,000 | — |
| Jun 17, 26 | Monia Brett P | director | A-Award | 25,000 | — |
| Jun 17, 26 | Wallace Peggy | director | A-Award | 25,000 | — |
| Jun 17, 26 | Richstone Ellen B | director | A-Award | 25,000 | — |
| Jun 17, 26 | Fletcher Aaron G.L. | director, 10 percent owner: | A-Award | 25,000 | — |
| May 1, 26 | Doyle John Brendan | officer: Chief Financial Officer | F-InKind | 8,567 @ $1.28 | $10.97K |
| Apr 16, 26 | Doyle John Brendan | officer: Chief Financial Officer | P-Purchase | 10,000 @ $1.13 | $11.30K |
| Apr 16, 26 | Ricciardi Lisa | director, officer: CEO & President | P-Purchase | 9,175 @ $1.10 | $10.09K |
TTM vs. 5-year historical average (annual ratios)
| Metric | CGTX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -3.7x | -3.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -2.4x | EPS est. -0.30 | Discount |
| Price / Book | 2.0x | 2.2x | In line |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -2.1x | -2.6x | Discount |
| Return on equity | -50.2% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.02 | 0.03 | Conservative |
| Piotroski / Altman Z | 1/9 | Z -0.88 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Oct 22, 2026 | 2026-10-22 06:06:25 | View |
| 10-Q | Aug 7, 2026 | 2026-08-07 07:30:59 | View |
| 8-K | Aug 6, 2026 | 2026-08-06 16:18:46 | View |
| 8-K | Jun 24, 2026 | 2026-06-24 07:39:06 | View |
| 4 | Jun 22, 2026 | 2026-06-22 17:18:09 | View |
| 4 | Jun 22, 2026 | 2026-06-22 17:16:44 | View |
| 4 | Jun 22, 2026 | 2026-06-22 17:14:24 | View |
| 4 | Jun 22, 2026 | 2026-06-22 17:12:53 | View |
| 4 | Jun 22, 2026 | 2026-06-22 16:00:07 | View |
| 8-K | Jun 18, 2026 | 2026-06-18 08:05:18 | View |
Proxy statement (DEF 14A) disclosures